Sugi Predict

Sugi Predict / Compounds / SCHEMBL424122

SCHEMBL424122

SCHEMBL424122

Cc1cccc(/C=N/Nc2cc(N3CCOCC3)cc(OCCOC(=O)N3CCCCC3)n2)c1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PIKFYVE Q9Y2I7 8/20 0.52
▸ FES P07332 1/20 0.52
▸ FER P16591 1/20 0.52
▸ TYK2 P29597 1/20 0.52
▸ FRK P42685 1/20 0.52
▸ SYK P43405 1/20 0.52
▸ CAMK1D Q8IU85 1/20 0.52
▸ IRAK4 Q9NWZ3 1/20 0.52
▸ MAPT P10636 7/20 0.51
▸ KDM4E B2RXH2 3/20 0.51
▸ LMNA P02545 2/20 0.51
▸ HPGD P15428 1/20 0.51
▸ ALDH1A1 P00352 2/20 0.43
▸ SENP7 Q9BQF6 1/20 0.43
▸ SENP6 Q9GZR1 1/20 0.43
▸ TDP1 Q9NUW8 1/20 0.41
▸ L3MBTL1 Q9Y468 2/20 0.41
▸ MEN1 O00255 1/20 0.40
▸ NPC1 O15118 1/20 0.40
▸ MAPK1 P28482 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL424123 1.00 PIKFYVE (0.52) PIKFYVEFESFERTYK2FRK
SCHEMBL425718 0.96 PIKFYVE (0.54) PIKFYVEFESFERTYK2FRK
SCHEMBL425719 0.96 PIKFYVE (0.54) PIKFYVEFESFERTYK2FRK
SCHEMBL425426 0.88 PIKFYVE (0.51) PIKFYVEFESFERTYK2FRK
SCHEMBL425425 0.88 PIKFYVE (0.51) PIKFYVEFESFERTYK2FRK
SCHEMBL428144 0.88 PIKFYVE (0.53) PIKFYVEFESFERTYK2FRK
SCHEMBL428145 0.88 PIKFYVE (0.53) PIKFYVEFESFERTYK2FRK
SCHEMBL423913 0.86 MAPT (0.55) PIKFYVEFESFERTYK2FRK
SCHEMBL423914 0.86 MAPT (0.55) PIKFYVEFESFERTYK2FRK
SCHEMBL430917 0.86 PIKFYVE (0.53) PIKFYVEFESFERTYK2FRK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1687004-A4 PYRIDINE COMPOUNDS SYNTA PHARMACEUTICALS CORP (US) 2009-04-08 — — EP claimed
JP-2007510747-A — — 2007-04-26 — — JP claimed
EP-1687004-A2 PYRIDINE COMPOUNDS Synta Pharmaceuticals Corporation (US) 2006-08-09 — — EP claimed
US-20050250774-A1 Pyridine compounds LSI FINANCING LLC, AS ADMINISTRATIVE AGENT 2005-11-10 — — US claimed
WO-2005046603-A2 PYRIDINE COMPOUNDS SYNTA PHARMACEUTICALS, CORP. (US) 2005-05-26 — — WO claimed
US-20150174132-A1 METHOD FOR TREATING B CELL REGULATED AUTOIMMUNE DISORDERS SYNTA PHARMACEUTICALS CORP (US) 2015-06-25 — — US disclosed
US-20150174132-A1 METHOD FOR TREATING B CELL REGULATED AUTOIMMUNE DISORDERS SYNTA PHARMACEUTICALS CORP (US) 2015-06-25 — — US disclosed
US-8173651-B2 Pyridine compounds SYNTA PHARMACEUTICALS CORPORATION (US) 2012-05-08 — — US disclosed
US-8173651-B2 Pyridine compounds SYNTA PHARMACEUTICALS CORPORATION (US) 2012-05-08 — — US disclosed
US-8173651-B2 Pyridine compounds SYNTA PHARMACEUTICALS CORPORATION (US) 2012-05-08 — — US disclosed
US-20120021434-A1 METHOD FOR TREATING B CELL REGULATED AUTOIMMUNE DISORDERS SYNTA PHARMACEUTICALS CORP. (US) 2012-01-26 — — US disclosed
US-20120021434-A1 METHOD FOR TREATING B CELL REGULATED AUTOIMMUNE DISORDERS SYNTA PHARMACEUTICALS CORP. (US) 2012-01-26 — — US disclosed
US-20090163708-A1 PROCESS FOR PREPARING MESYLATE SALTS OF IL-12 INHIBITORY COMPOUNDS SYNTA PHARMACEUTICALS CORP. (US) 2009-06-25 — — US disclosed
US-20080167300-A1 PYRIDINE COMPOUNDS MADRIGAL PHARMACEUTICALS, INC. 2008-07-10 — — US disclosed
US-20080167300-A1 PYRIDINE COMPOUNDS MADRIGAL PHARMACEUTICALS, INC. 2008-07-10 — — US disclosed
US-7338951-B2 Pyridine compounds SYNTA PHARMACEUTICALS CORP. (US) 2008-03-04 — — US disclosed
US-7338951-B2 Pyridine compounds SYNTA PHARMACEUTICALS CORP. (US) 2008-03-04 — — US disclosed
US-20070032493-A1 Method for treating B cell regulated autoimmune disorders SYNTA PHARMACEUTICALS CORP. (US) 2007-02-08 — — US disclosed
US-20070032493-A1 Method for treating B cell regulated autoimmune disorders SYNTA PHARMACEUTICALS CORP. (US) 2007-02-08 — — US disclosed
US-20070032493-A1 Method for treating B cell regulated autoimmune disorders SYNTA PHARMACEUTICALS CORP. (US) 2007-02-08 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080167300-A1 PYRIDINE COMPOUNDS IL2, IL4, IL6 PIKFYVE 1593/4885FES 1599/4885FER 1377/4885
US-20150174132-A1 METHOD FOR TREATING B CELL REGULATED AUTOIMMUNE DISORDERS REL, NFATC1, BCL6 PIKFYVE 4150/4885FES 4592/4885FER 2503/4885
US-20050250774-A1 Pyridine compounds IL2, IL4, IL6 PIKFYVE 1593/4885FES 1599/4885FER 1377/4885
US-20090163708-A1 PROCESS FOR PREPARING MESYLATE SALTS OF IL-12 INHIBITORY COMPOUNDS IL17A, IL23R, IL2 PIKFYVE 2941/4885FES 1524/4885FER 2106/4885
US-20070032493-A1 Method for treating B cell regulated autoimmune disorders REL, NFATC1, BCL6 PIKFYVE 4150/4885FES 4592/4885FER 2503/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.